Disease Overview：Acute Myeloid Leukemia（AML）
Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by rapid proliferation and impaired differentiation of myeloid progenitor cells in the bone marrow and peripheral blood. It arises from genetic mutations—such as FLT3, NPM1, CEBPA, or core-binding factor abnormalities—that disrupt normal hematopoiesis, leading to cytopenias, infection risk, bleeding, and organ infiltration. Diagnosis relies on morphologic assessment, flow cytometry, cytogenetics, and molecular profiling per WHO and ELN guidelines. Treatment typically involves induction chemotherapy (e.g., “7+3” regimen with cytarabine and anthracycline), followed by consolidation therapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT) for eligible patients. Risk stratification guides therapeutic intensity and transplant timing, with measurable residual disease (MRD) monitoring increasingly informing clinical decisions.
China offers compelling advantages for AML care: its top-tier oncology centers—many affiliated with universities like Peking Union Medical College Hospital and Fudan University Shanghai Cancer Center—maintain internationally trained hematologists and robust clinical trial portfolios, including novel FLT3 inhibitors and CD33-targeted therapies. Advanced infrastructure includes next-generation sequencing platforms, digital pathology integration, and high-resolution HLA typing for donor matching. Five-year overall survival rates for standard-risk AML approach 60–70% in leading institutions, with allo-HSCT outcomes comparable to Western benchmarks. Crucially, treatment costs—including comprehensive diagnostics, chemotherapy cycles, and transplant—typically run 40–60% lower than in the US or EU, without compromising protocol adherence or supportive care standards.
As a dedicated medical tourism agency, we facilitate seamless access for international patients: vetting accredited hospitals, coordinating appointments with AML specialists, clarifying all-inclusive pricing upfront, arranging visas and accommodation, and providing bilingual case management from diagnosis through follow-up.
Acute Myeloid Leukemia: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Acute Myeloid Leukemia (AML)
Non-Surgical/Medical Therapy
*Induction Chemotherapy (7+3 regimen)*
- •Eligibility: Fit adults ≤60 years, ECOG 0–2, adequate organ function
- •Cost Breakdown (USD):
- Daunorubicin (60 mg/m² × 3 days): $1,240 - Supportive care (IV antibiotics, G-CSF, transfusions): $2,900 - Daily lab monitoring (CBC, coagulation, electrolytes, LDH): $420 - Bone marrow aspiration/biopsy (day 14/28): $380
*Targeted Therapy (FLT3-mutated AML)*
- •Eligibility: FLT3-ITD or TKD mutation confirmed by NGS
- •Cost Breakdown (USD):
- Gilteritinib (120 mg/day): $6,800/month - NGS panel (FLT3, NPM1, CEBPA, TP53): $490
Procedural/Interventional Options
*Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)*
- •Eligibility: CR1 high-risk AML, age ≤65, HLA-matched donor (sibling or MUD), no active infection or severe comorbidity
- •Preoperative Workup (USD):
- Donor lymphocyte typing (HLA-A/B/C/DR/DQ): $650 - Cardiac echo + renal scintigraphy: $510
- •Procedure & Hospitalization (USD):
- Stem cell infusion + 30-day inpatient care: $18,900 - GVHD prophylaxis (tacrolimus + methotrexate): $1,260
Special/Complex Condition Management
- •Relapsed/Refractory AML: Venetoclax + azacitidine (3-month course): $12,400
- •AML with TP53 mutation: Hypomethylating agent + clinical trial enrollment (no drug cost; screening labs: $320)
- •CNS involvement: Intrathecal cytarabine × 4 doses + cranial MRI: $1,680
Quick Selection Guide
- •Age <60, fit, standard-risk: Induction chemo → $6,790 total
- •Age 60–65, FLT3-mutated: Gilteritinib + supportive care → $7,220/month, lower toxicity than chemo
- •High-risk cytogenetics (e.g., complex karyotype): Proceed to allo-HSCT in CR1 → $22,740 pre-transplant + $23,860 transplant = $46,600 total
- •Age >70 or significant comorbidities (COPD, CKD stage 3): Low-intensity therapy (azacitidine ± venetoclax) → $8,900–$12,400/month, prioritizes quality of life
- •Budget-constrained (<$5,000): Generic cytarabine + daunorubicin induction at public hospital tier-3A → $4,200, includes mandatory transfusion support and infection management
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Acute Myeloid Leukemia Medical Vacation Packages
Curated transparent all-inclusive packages combining Acute Myeloid Leukemia treatment with China top medical destinations:
